The pharmaceutical industry continues to explore ways to achieve operational excellence across their organizations—not only in manufacturing, but in areas such as finance, research and development (R&D), and safety. While M&A activity has intensified in recent years, many firms are still trying to optimize their acquisitions to realize the full value of post-deal synergies. Overall, the trend among all life-sciences organizations toward patient-centric care models may have the greatest impact.